Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

Though there are very few characters in MASH who aren't beloved by audiences and critics, these individuals rise to the top ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

This local sensation mashes up pop and rock hits with a full brass section, turning every show into a high-energy singalong.

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands.

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

It took a month, but this is the Phillies lineup that was advertised. They pounded the Rays on Wednesday to with their fourth ...